Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL444824 | 0.93 | NR3C1 (0.77) | NR3C1PGR | |
| SCHEMBL14185602 | 0.89 | NR3C1 (0.79) | NR3C1PGR | |
| SCHEMBL850923 | 0.89 | NR3C1 (0.71) | NR3C1PGR | |
| Trifluoroacetic Acid SCHEMBL2999259 | 0.88 | NR3C1 (0.89) | NR3C1PGR | |
| Hydrochloric Acid SCHEMBL834885 | 0.88 | NR3C1 (0.70) | NR3C1PGR | |
| SCHEMBL12101194 | 0.87 | NR3C1 (0.72) | NR3C1PGR | |
| SCHEMBL835586 | 0.87 | NR3C1 (0.72) | NR3C1PGR | |
| SCHEMBL412277 | 0.87 | NR3C1 (0.72) | NR3C1PGR | |
| SCHEMBL836035 | 0.85 | NR3C1 (1.00) | NR3C1PGR | |
| SCHEMBL836034 | 0.85 | NR3C1 (1.00) | NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252770-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252770-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| US-8143290-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143290-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20120065173-A1 | CHEMICAL COMPOUNDS | BERGER MARKUS (DE) | 2012-03-15 | — | — | US | disclosed |
| US-20120065173-A1 | CHEMICAL COMPOUNDS | BERGER MARKUS (DE) | 2012-03-15 | — | — | US | disclosed |
| US-8030340-B2 | Moderators of glucocorticoids receptor; antiinflamamtory agents; chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2011-10-04 | — | — | US | disclosed |
| US-8030340-B2 | Moderators of glucocorticoids receptor; antiinflamamtory agents; chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2011-10-04 | — | — | US | disclosed |
| US-20110071194-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110071194-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20100197644-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197644-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-05 | — | — | US | disclosed |
| US-7728030-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2010-06-01 | — | — | US | disclosed |
| US-7728030-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2010-06-01 | — | — | US | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080207721-A1 | Chemical compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207721-A1 | Chemical compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214641-A1 | Chemical compounds 572 | ABCG2, ABCB1, CYP11B2 | NR3C1 2841/4885PGR 1005/4885 |
| US-20100197644-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | NR3C1 2841/4885PGR 1005/4885 |
| US-20080207721-A1 | Chemical compounds | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 263/4885 |
| US-20120252770-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | NR3C1 2841/4885PGR 1005/4885 |
| US-20120065173-A1 | CHEMICAL COMPOUNDS | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 281/4885 |
| US-20110071194-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | NR3C1 2841/4885PGR 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.